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SHORT COMMUNICATION
Dexamethasone decreases urokinase plasminogen activator mRNA
stability in MAT 13762 rat mammary carcinoma cells
B.R. Henderson & R.F. Kefford
Medical Oncology Unit, Department ofMedicine, University ofSydney, Westmead Hospital, Westmead, New South Wales 2145,
Australia.
Summary The glucocorticoid dexamethasone was observed to decrease urokinase plasminogen activator
(uPA) RNA levels from within 1 h of treatment of MAT 13762 mammary adenocarcinoma cells. The drug did
not alter the rate of uPA gene transcription in these cells, but decreased the stability of cytoplasmic uPA
mRNA transcripts. Results from cycloheximide and actinomycin D experiments indicated that the dexa-
methasone-mediated reduction in uPA RNA required both new protein and RNA synthesis. Based on these
results, we propose that dexamethasone induces a short-lived protein(s) which down-regulates uPA RNA levels
post-transcriptionally in these metastatic tumour cells.
Urokinase plasminogen activator (uPA) is a serine protease
capable of cell-surface attachment and widely implicated as
an initiator of tumour cell invasion during the metastatic
process (Dano et al., 1985; Blasi et al., 1987). Expression of
the uPA gene is known to be regulated transcriptionally (see
Rorth et al., 1990 and references therein), and also post-
transcriptionally in the cytoplasm (Ziegler et al., 1990; Altus
& Nagamine, 1991) and in the nucleus (Henderson et al.,
1992a,b). The synthetic glucocorticoid, dexamethasone, exerts
a negative influence on uPA mRNA levels in human tumour
cell-lines (Busso et al., 1986; Busso et al., 1987; Medcalf et
al., 1988), at a level which includes decreased transcription
(Medcalf et al., 1988). We observed a similar effect of dexa-
methasone during our studies on uPA gene regulation in
MAT 13762 rat mammary carcinoma cells, which normally
express high levels of uPA mRNA and protein (Henderson &
Kefford, 1991; Henderson et al., 1992a). In this communica-
tion, we report an investigation of the mechanism(s) by
which dexamethasone decreases uPA mRNA levels in these
metastatic tumour cells.
Dexamethasone decreases uPA RNA levels
Densitometric quantitation of Northern blots revealed that
10-7 M dexamethasone reduced uPA RNA levels from within
1 h, and resulted in a 4-fold decrease by 20 h (see Figure la).
The glucocorticoid was equally effective at concentrations of
10-6 to 10-8 M (data not shown). Cycloheximide (CHX)
inhibits protein synthesis in MAT 13762 cells by >95%
(data not shown), and increased uPA RNA levels approx-
imately 2-fold in 4 h in these cells (Figure lb). Pretreatment
of MAT 13762 cells with 10 itg ml-' cycloheximide complete-
ly blocked the effect of dexamethasone on uPA RNA levels
(Figure lb), as did addition of the transcription inhibitor,
actinoniiycin D (Figure lc). These results suggest that dexa-
methasone requires the continued synthesis of RNA and
protein molecules to reduce uPA RNA levels in MAT 13762
cells. In addition, pretreatment with 10-fold molar excess of
the glucocorticoid antagonist RU38486 blocked the hormone
effect (data not shown), suggesting that dexamethasone is
acting via the glucocorticoid receptor.
In contrast to the situation reported for human cell-lines
(Busso et al., 1987), dexamethasone did not repress uPA gene
transcription in MAT 13762 cells. RNA blot analysis and a
nuclear run-on assay showed that whilst dexamethasone
decreased both cytoplasmic and mature nuclear uPA RNA
pools (Figure 2a), the rate of uPA gene transcription was
unaltered (Figure 2b). The exact mechanism by which the
nuclear uPA RNA level (which is unusually high relative to
the cytoplasmic pool in MAT 13762 cells) is decreased by the
drug is at present unclear, however the effect was gene-
specific relative to a glyceraldehyde 3-phosphate dehydro-
genase (GAPDH) reference gene (Figure 2a).
Dexamethasone acts at a post-transcriptional level
The half-life of uPA RNA was estimated to be >24h by
actinomycin D chase (Figure 2c), suggesting that the rapid
decrease observed in uPA RNA might result from an effect
of dexamethasone on uPA cytoplasmic RNA stability. This
was confirmed by a 3H-uridine pulse-chase assay (Figure 2d);
a technique which avoids the need to use transcription inhi-
biting drugs, and which revealed that dexamethasone
decreased the uPA RNA half-life to about 5.5 h. This is a
novel finding with regard to uPA gene regulation. It should
be pointed out however, that similar studies of uPA regula-
tion by dexamethasone in human breast cancer cell-lines also
reported a long half-life of uPA mRNA prior to drug treat-
ment (Busso et al., 1986), suggesting that hormonal modula-
tion of cytoplasmic uPA mRNA stability may be a more
general phenomenon.
Dexamethasone is known to decrease the stability of other
mRNAs including those encoded by the genes for c-myc
(Maroder et al., 1990), interleukin-IP (Lee et al., 1988),
interferon-I (Peppel et al., 1991) and the monocyte chemo-
tactic-activating factor (MCAF) gene (Mukaida et al., 1991).
A structural feature common to all of the transcripts encoded
by these genes, and in particular the uPA genes (Henderson
& Kefford, 1991), is the presence of 3'-untranslated region
A + U rich sequences, which signal degradation of cytokine
and certain oncogene mRNAs (Shaw & Kamen, 1986;
Schuler & Cole, 1988). Indeed, deletion of the A + U region
from interferon-0 gene constructs abolished the enhancing
effect of dexamethasone on mRNA turnover (Peppel et al.,
1991). All of the above-mentioned genes excluding interferon-
I, were reported to require synthesis of new protein(s) to
manifest modulation of mRNA turnover by dexamethasone.
It therefore seems apparent that in several situations, dexa-
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Figure 1 Quantitation of uPA RNA from MAT 13762 cells. a,
Northern blot analysis was performed with 10 ig samples of
cytoplasmic RNA isolated from cells at different time (h) follow-
ing treatment with 10-7 M dexamethasone. Similar analysis was
made on cells untreated or treated for 4 h with b, 10-7 M dexa-
methasone, 10 lag ml-' cycloheximide, or 4 h dexamethasone add-
ed 30 min after cycloheximide and c, 10-7 M dexamethasone,
10tg ml- actinomycin D (AD), both dexamethasone and AD.
Control samples were treated with agent solvent (0.01% ethanol).
Equivalent RNA loading was confirmed by reprobing with a
GAPDH cDNA (not shown). The pRAT-UKI uPA cDNA probe
and all procedures have recently been described (Henderson et
al., 1992b). Relative intensities of X-ray signals were graphed in
arbitrary units, where control values are set to 100%. The results
shown are typical of two independent experiments.
methasone modulates mRNA turnover indirectly through the
action of a possibly short-lived protein(s). Since for several of
these dexamethasone-controlled mRNAs (uPA, interleukin-
l, MCAF) synthesis of new RNA molecules is also required
for its effect, dexamethasone may act by increasing transcrip-
tion of a gene which encodes the labile protein responsible
for enhanced mRNA turnover. The requirement for gluco-
corticoid receptor, a known transcription modulator (see
Jonat et al., 1990), indirectly supports this argument. In this
scenario, the induced protein may be an RNase, an A + U
RNA-binding protein (reviewed in Hentze, 1991) which sig-
nals RNA degradation, or perhaps an undefined accessory
factor. The alternate possibility that glucocorticoid receptor
itself needs to be continuously synthesised to observe the
effect is perhaps less likely, but remains to be experimentally
excluded.
UPA UAP
MAT 13762 ±
actinomycin D --,
0 4 81624
>- 10o
0
0
*-
CK
Sc
0 uPA
GAP 1c
-- -uPA
GAP
0 5 10 15 20 24
(h)
-W ff- 5.0
05
to 1.0
0.5
0.
CL)
C< 0.1
Pulse chase
[3H] uridine
(-)
0
I
0 4 8 12 16
(h)
Figure 2 Mechanism of dexamethasone action. a, Northern
analysis of 10 ig of total cytoplasmic (C) and nuclear (N) RNA
isolated from MAT 13762 cells untreated (-) or treated (+) with
10-6 M dexamethasone for 4 h. A 7 kb nuclear uPA preRNA is
indicated by an arrow. b, Nuclear run-on assay. Nuclei were
isolated from MAT 13762 cells untreated or treated 4 h with
10-6 M dexamethasone. Target genes are uPA, pGem4z (G4z),
a-tubulin (TUB), GAPDH (GAP) and a 1 jg aliquot of sheared
total DNA (TOT), c, MAT 13762 cells were treated with actino-
mycin D for various times up to 24h, and cytoplasmic RNA
analysed by Northern blotting. Signal intensities for uPA and
GAPDH (GAP) genes were quantitated by densitometry and
plotted in arbitrary units on a semi-log graph, from which RNA
half-lives were estimated. d, Analysis of 3H-uridine pulse-labelled
RNA. Following a 20 h pulse with 40 JLCi ml-' [5,6-3H]-uridine
(Amersham, UK), uPA 3H-RNA signals were quantitated by
scintillation counting following chase in the presence (+) or
absence (-) of 10-6 M dexamethasone. Each data point repre-
sents the mean of three 20 min countings. Values shown represent
labelled uPA RNA, minus pGem4z values. uPA RNA half-life
was estimated from the best-fit slope, determined by linear regres-
sion analysis. Details of all techniques and probes are as des-
cribed (Henderson et al., 1992b). All data presented are taken
from single experiments which were repeated at least once with
similar results.
Implications of dexamethasone modulation of uPA mRNA
stability
The effects of cycloheximide on stability of cytoplasmic uPA
mRNA have been investigated in porcine LLC-PK, cells both
in vivo (Altus et al., 1987) and in vitro (Altus & Nagamine,
1991). In log-phase LLC-PK1 cells, following transcriptional
induction of uPA mRNA by the peptide hormone calcitonin,
the normal half-life of uPA mRNA can be extended from 1 h
to >20 h by cycloheximide treatment (Altus & Nagamine,
1991). Compelling evidence has been presented from the
results of in vitro decay experiments to suggest that in LLC-
PK, cells, cycloheximide prolongs uPA mRNA stability by
blocking synthesis of a short-lived repressor protein which
directly or indirectly associates with uPA mRNA (Altus &
Nagamine, 1991). The nature of this protein awaits defini-
tion. It is interesting to note that the modulation of uPA
mRNA stability in LLC-PK, cells is the reverse situation to
that observed in MAT 13762 cells. In MAT 13762 cells, the
steady-state uPA mRNA half-life is > 16 h, which is com-
parable to that induced in LLC-PK, cells following cyclohex-
imide treatment. This suggests the intriguing possibility that
dexamethasone might induce a similar labile RNA-destabilis-
ing protein(s) to that which is constitutively expressed in
LLC-PK, cells.
The above hypothesis does not exclude involvement of
other mRNA degradation components. In particular, the
mechanism(s) by which dexamethasone enhances mRNA
turnover is unlikely to be identical for all mRNAs and in all
cell types. This is illustrated by the observation that whilst
dexamethasone is known to destabilise c-myc mRNA in leu-
kaemic T-cells (Maroder et al., 1990), c-myc mRNA levels
were not altered by this drug in MAT 13762 cells (data not
shown). Similarly, in LLC-PKI cells, c-myc and uPA mRNAs
followed distinct degradation pathways (Altus & Nagamine,
1991). The primary sequence element(s) and the short-lived
protein(s) responsible for uPA mRNA instability are at pre-
sent unknown, however the means to identify these deter-
minants may be at hand. The availability of cell model
systems in which the proposed unstable repressor protein can
be either depleted (by cycloheximide; Altus & Nagamine,
1991) or induced (by dexamethasone; this study), may offer
alternate approaches to its eventual identification.
It is clear from the data presented in this study, that
posttranscriptional control of the uPA gene in rat mammary
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carcinomas is not restricted primarily to the nucleus (Hender-
son et al., 1992a,b), but that uPA mRNA is also hormonally
modulated in the cytoplasm of certain tumour cells. The
potential of dexamethasone to repress not only uPA gene
transcription (Busso et al., 1987; Medcalf et al., 1988), but
also uPA mRNA stability, could provide a more general
explanation for the commonly observed repression of uPA
mRNA synthesis mediated by this drug in different tumour
cell lines.
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